Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its ...

Union momentum grows in Ireland’s €100bn pharma sector as Trump’s tariff threats and weak labour laws fuel worker unrest ...

Bengaluru: HealthCare Global Enterprises (HCG), one of Bengaluru’s leading cancer treatment hospitals, has come under serious ...

Charles E. Hamner Jr., a highly respected and accomplished scientist, university administrator and pharmaceutical executive who led the North Carolina Biotechnology Center during its formative years, ...

Welcome to our live blog tracking the latest news and developments from China. Stay updated with real-time insights into the ...

Eli Lilly reported impressive data at the recent American Diabetes Association ('ADA') conference. Its robust pipeline will ...

Novo Nordisk (NVO) and Eli Lilly & Co. (LLY), the global leaders in obesity medications, are now facing their first major ...

In the latest quarter, 7 analysts provided ratings for Eli Lilly LLY +1.30% Get Free Report , showcasing a mix of bullish and ...

The acquisition aligns with Eli Lilly’s broader diversification strategy beyond its core diabetes and obesity treatment portfolio.

Eli Lilly’s $1.3 billion acquisition of Verve Therapeutics marks a strategic expansion into cardiovascular genetic medicine. The pharmaceutical giant paid a premium of about 113% over Verve’s ...

Part 1 — Eli Lilly’s CFO on-stage phrasing about GLP-1 compounding leads to a stir At the Goldman Sachs 46th Annual Global Healthcare Conference last week, Eli Lilly's CFO Lucas Montarce said ...

Citi stated that as the obesity space evolves from injectables to convenient orals, such as orforglipron, the emergence of a “dynamic” consumer-centric market is possible, and LillyDirect by Eli Lilly ...